Impact of Huisheng Oral Solution Combined with Immune Checkpoint Inhibitors and Chemotherapy in Patients with Stage III-IV Non-Small Cell Lung Cancer: A Retrospective Analysis
Yifeng Bai, Jirui Wang, Linsheng Song, Honglin Hu, Lan Yang, Gang Feng, Jie Chen, Heling Peng, Shengkun Peng · Journal of Cancer · 2025
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2025
Abstract
Background: To evaluate the impact of Huisheng Oral Solution (HSOS) in conjunction with immune checkpoint inhibitors (ICIs) and chemotherapy on patients with stage III-IV non-small cell lung cancer (NSCLC).Methods: This retrospective study included patients with stage III-IV NSCLC who were treated at Sichuan Provincial People's Hospital from May 2018 to June 2021.Patients were categorized into two groups: the ICIs & Chemo Group and the ICIs & Chemo & HSOS Group, based on the therapies administered.The disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and immune-related adverse events (irAEs) were assessed.Results: A total of 185 patients were included, with 109 patients in ICIs & Chemo & HSOS Group.The ICIs & Chemo & HSOS Group exhibited significantly enhanced DCR (90.83% vs.
71.05%,p=0.001) compared to the ICIs & Chemo Group.The ORR was not statistically significant between the two groups (31.19% vs. 27.63%,p=0.628).Patients in the ICIs & Chemo & HSOS Group had significantly longer PFS (HR=0.47,95% CI: 0.29-0.75,p<0.001) and OS (HR=0.58,95% CI: 0.33-1.00,p=0.037) than the ICIs & Chemo Group.In terms of irAEs, nephrotoxicity (5.77% vs. 15.25%,p=0.044), checkpoint inhibitor-related pneumonitis (CIP) (2.75% vs. 11.84%,p=0.014), and cardiotoxicity (0% vs.
13.04%,p=0.026) were significantly lower in the ICIs & Chemo & HSOS Group.Conclusion: The addition of HSOS to ICIs and chemotherapy may enhance DCR, PFS, and OS, while concurrently reducing irAEs in patients with stage III-IV NSCLC.These findings suggest that HSOS may serve as a promising adjunct to ICI-based therapies.Further prospective studies are warranted to validate these results.
Open the resolved locator · 10.7150/jca.116142
Metadata licence: OpenAlex metadata (CC0)